Histone deacetylase inhibitors suppress aggressiveness of head and neck squamous cell carcinoma via histone acetylation-independent blockade of the EGFR-Arf1 axis

Abstract Background A promising arsenal of histone deacetylase (HDAC)-targeted treatment has emerged in the past decade, as the abnormal targeting or retention of HDACs to DNA regulatory regions often occurs in many cancers. Head and neck squamous cell carcinoma (HNSCC) is one of the most aggressive...

Full description

Bibliographic Details
Main Authors: Leilei He, Lixia Gao, Chloe Shay, Liwei Lang, Fenglin Lv, Yong Teng
Format: Article
Language:English
Published: BMC 2019-02-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13046-019-1080-8